- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Walpar Nutritions Limited — Results, 15-05-2025: Integrated Filing- Financial
Walpar Nutritions has announced a board meeting to consider the financial results for the quarter and half-year ended March 31, 2025.
1) Revenue Performance: Consolidated revenue rose 24.5% YoY to ₹39.19 Cr for the half-year, driven by growth in pharmaceutical, nutraceutical, herbal, and ayurvedic segments. Standalone revenue grew even faster at 36% to ₹35.31 Cr.
2) Profitability and EPS: Net profit attributable to owners stood at ₹1.04 Cr, slightly down from ₹1.18 Cr last year, with basic EPS declining to ₹1.10 from ₹1.26. Profit before tax improved to ₹2.07 Cr from ₹1.69 Cr. Margins expanded moderately due to better operating leverage offsetting inflationary pressures. Standalone net profit was ₹0.58 Cr (prev. ₹0.85 Cr) with EPS of ₹0.61.
3) Operational Costs: Consolidated expenses increased to ₹37.12 Cr mainly from higher raw material costs (₹29.85 Cr vs ₹24.14 Cr) and employee benefits (₹4.69 Cr vs ₹3.97 Cr). Finance costs dropped sharply to ₹0.32 Cr from ₹0.57 Cr, reflecting improved cost control. Depreciation remained steady.
4) Key Metrics: EBITDA growth aligned with revenue, supported by effective inventory management. Operating cash flow was strong at ₹4.06 Cr despite rising working capital needs.
5) Balance Sheet / Cash Flow Health: Long-term debt reduced to ₹3.53 Cr from ₹4.08 Cr, short-term debt stable around ₹4.32 Cr, and cash balances increased to ₹1.59 Cr. Capex rose to ₹2.28 Cr indicating ongoing capacity expansion. Overall, the balance sheet looks comfortable with growing reserves.
6) Management Outlook: Though no direct commentary, related party dealings suggest continued expansion through subsidiaries, reinforcing focus on wellness and nutrition.
Final Takeaway: Walpar Nutritions shows positive top-line momentum and tighter financing costs, with expansion spending indicating confidence in future growth. Retail investors should monitor margin sustainability and working capital trends as the company scales its core health-focused portfolio.